Figure 3.

Patient antibody staining has the same structural components as deamidation. A, Mutating residue G369 decreases staining by patients' antibodies to different extents (n = 8–9 patients, ***p < 0.001, one-way ANOVA plus Tukey's post hoc testing). B, Mutation of G369 to residues that increasingly slow deamidation in model peptides correlate with decreased patient antibody staining (r² = 0.87, nonlinear correlation, one phase decay; where wt is wild type). C, Mutation of N368 to D maintains antibody staining at a decreased level while dual mutation of N368D/G369I blocks staining (n = 8–9 patients, ***p < 0.001, one-way ANOVA plus Tukey's post hoc testing).